Eyepoint Accounts Payable from 2010 to 2025

EYPT Stock  USD 6.21  0.42  6.33%   
Eyepoint Pharmaceuticals Accounts Payable yearly trend continues to be comparatively stable with very little volatility. Accounts Payable is likely to outpace its year average in 2025. Accounts Payable is the amount Eyepoint Pharmaceuticals owes to suppliers or vendors for products or services received but not yet paid for. It represents Eyepoint Pharmaceuticals' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2003-06-30
Previous Quarter
7.3 M
Current Value
11.7 M
Quarterly Volatility
3.6 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Eyepoint Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eyepoint Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 13.3 K or Total Revenue of 45.4 M, as well as many indicators such as Price To Sales Ratio of 9.21, Dividend Yield of 0.0 or PTB Ratio of 1.18. Eyepoint financial statements analysis is a perfect complement when working with Eyepoint Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Eyepoint Pharmaceuticals Correlation against competitors.
For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.

Latest Eyepoint Pharmaceuticals' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Eyepoint Pharmaceuticals over the last few years. An accounting item on the balance sheet that represents Eyepoint Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Eyepoint Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Eyepoint Pharmaceuticals' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eyepoint Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Eyepoint Accounts Payable Regression Statistics

Arithmetic Mean4,501,814
Geometric Mean2,160,304
Coefficient Of Variation99.00
Mean Deviation3,833,942
Median4,811,000
Standard Deviation4,456,585
Sample Variance19.9T
Range12M
R-Value0.86
Mean Square Error5.6T
R-Squared0.74
Significance0.000021
Slope803,206
Total Sum of Squares297.9T

Eyepoint Accounts Payable History

202512.3 M
202411.7 M
20236.5 M
20225.9 M
20217.4 M
20204.8 M
201911.4 M

About Eyepoint Pharmaceuticals Financial Statements

Eyepoint Pharmaceuticals shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although Eyepoint Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Eyepoint Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Eyepoint Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Accounts Payable11.7 M12.3 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Eyepoint Stock Analysis

When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.